CWM
VRTX icon

Cedar Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cedar Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12
Closed -$5.63K – 304
2024
Q2 		$5.63K Hold
12
– – ﹤0.01% 257
2024
Q1 		$5.02K Buy
+12
New +$5.07K ﹤0.01% 283
2022
Q3 		– Sell
-319
Closed -$90K – 347
2022
Q2 		$90K Sell
319
-5
-2% -$1.34K 0.04% 137
2022
Q1 		$85K Sell
324
-45
-12% -$10.7K 0.03% 147
2021
Q4 		$81K Sell
369
-156
-30% -$30.3K 0.03% 157
2021
Q3 		$95K Buy
525
+81
+18% +$15.8K 0.04% 133
2021
Q2 		$90K Buy
+444
New +$92.9K 0.04% 143
2018
Q3 		– Sell
-28
Closed -$5K – 230
2018
Q2 		$5K Buy
+28
New +$4.34K ﹤0.01% 169
2017
Q4 		– Sell
-15
Closed -$2K – 148
2017
Q3 		$2K Hold
15
– – ﹤0.01% 126
2017
Q2 		$2K Hold
15
– – ﹤0.01% 128
2017
Q1 		$2K Hold
15
– – ﹤0.01% 128
2016
Q4 		$1K Hold
15
– – ﹤0.01% 129
2016
Q3 		$1K Hold
15
– – ﹤0.01% 119
2016
Q2 		$1K Buy
+15
New +$1.3K ﹤0.01% 125

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cedar Wealth Management's VRTX Position: Q3 2024 in Review

Cedar Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 12 shares — an estimated $5.63K sold.

Cedar Wealth Management first reported a position in VRTX in Q2 2016 and held it in 14 quarters. The position peaked at $95K in Q3 2021. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Cedar Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cedar Wealth Management sold 12 Vertex Pharmaceuticals shares in Q3 2024, an estimated $5.63K.
  • Cedar Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 14 quarters.
  • Cedar Wealth Management's Vertex Pharmaceuticals position peaked at $95K in Q3 2021.
  • 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Cedar Wealth Management's 13F filing for Q3 2024, filed 8 Nov 2024.